BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Sold by Peregrine Capital Management LLC

Peregrine Capital Management LLC cut its stake in BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) by 2.9% in the fourth quarter, Holdings Channel reports. The fund owned 285,648 shares of the medical equipment provider’s stock after selling 8,646 shares during the period. Peregrine Capital Management LLC’s holdings in BioLife Solutions were worth $5,199,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Pier Capital LLC increased its stake in shares of BioLife Solutions by 0.3% in the 3rd quarter. Pier Capital LLC now owns 276,734 shares of the medical equipment provider’s stock worth $6,296,000 after acquiring an additional 945 shares during the last quarter. Maryland State Retirement & Pension System increased its position in shares of BioLife Solutions by 15.9% during the 3rd quarter. Maryland State Retirement & Pension System now owns 13,938 shares of the medical equipment provider’s stock worth $317,000 after purchasing an additional 1,914 shares during the last quarter. Greenwood Capital Associates LLC acquired a new stake in shares of BioLife Solutions during the 3rd quarter worth about $339,000. Quantbot Technologies LP acquired a new stake in shares of BioLife Solutions during the 3rd quarter worth about $212,000. Finally, Meros Investment Management LP increased its position in shares of BioLife Solutions by 309.5% during the 2nd quarter. Meros Investment Management LP now owns 198,638 shares of the medical equipment provider’s stock worth $2,743,000 after purchasing an additional 150,134 shares during the last quarter. 89.82% of the stock is owned by institutional investors and hedge funds.

BioLife Solutions Stock Performance

Shares of BLFS opened at $21.52 on Friday. The stock has a 50-day simple moving average of $23.12 and a 200-day simple moving average of $21.97. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.76 and a current ratio of 3.68. The stock has a market capitalization of $920.41 million, a PE ratio of -8.68 and a beta of 1.86. BioLife Solutions, Inc. has a 1 year low of $10.40 and a 1 year high of $26.96.

Analyst Ratings Changes

A number of analysts recently issued reports on BLFS shares. Oppenheimer reissued an “outperform” rating and set a $28.00 price objective on shares of BioLife Solutions in a research report on Monday, March 6th. Stephens cut their price objective on BioLife Solutions from $31.00 to $27.00 and set an “overweight” rating for the company in a research report on Friday. Finally, StockNews.com started coverage on BioLife Solutions in a research report on Thursday. They set a “sell” rating for the company.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, EVP Aby J. Mathew sold 10,000 shares of BioLife Solutions stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $17.77, for a total transaction of $177,700.00. Following the transaction, the executive vice president now owns 252,826 shares of the company’s stock, valued at $4,492,718.02. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, EVP Aby J. Mathew sold 10,000 shares of BioLife Solutions stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $17.77, for a total value of $177,700.00. Following the sale, the executive vice president now directly owns 252,826 shares in the company, valued at $4,492,718.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CRO Marcus Schulz sold 1,000 shares of BioLife Solutions stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $25.02, for a total value of $25,020.00. Following the completion of the sale, the executive now owns 43,437 shares in the company, valued at $1,086,793.74. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 59,454 shares of company stock valued at $1,359,106. Corporate insiders own 3.30% of the company’s stock.

BioLife Solutions Profile

(Get Rating)

BioLife Solutions, Inc engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services.